Adam Torres and Benjamin Lightburn discuss mental health.
Subscribe: iTunes / Spotify
Apply to be a guest on our podcast here
Show Notes:
Filament Health, recently became the first psychedelic drug discovery and development company to receive FDA approval to conduct a natural psychedelic clinical trial, which they’re presently performing in partnership with the University of California, San Francisco. In this episode, Adam Torres interviewed Benjamin Lightburn, CEO of Filament Health. Explore the current state of mental health and how companies like Filament Health are working towards solutions.
About Benjamin Lightburn
Benjamin Lightburn is the CEO and Co-Founder of Filament Health Corp. He’is also on the board of Bast Fibre Technologies, Inc. In the past Mr. Lightburn was a Business Manager at Radient Technologies, Inc. and Chief Executive Officer of Mazza Innovation Ltd. He also received an MBA from Sauder School of Business and an undergraduate degree from Queen’s University.
About Filament Health
Filament Health believes that standardized, naturally-derived psychedelic medicines can improve the lives of millions of people suffering from treatable conditions. Our mission is to see them in the hands of everyone who needs them, as soon as possible.
